April 26, 2019

Barry D. Brooks, M.D., Joins NCODA Executive Council


Cazenovia, NY – The National Community Oncology Dispensing Association, Inc. (NCODA)is pleased to announce the addition of Barry D. Brooks, M.D. to their Executive Council. Dr. Brooks joined the Council in April.

Barry D. Brooks, M.D., is a hematologist and medical oncologist with Texas Oncology and for 17 years has worked as physician-lead on the Drug Contracting committee of US Oncology. He was Chair of P&T from 2011 to 2018 and now serves as Medical Director of Oral Oncolytics for USON. He is the author of many publications and abstracts in the field of oncology. ”Being part of NCODA is a great honor. I believe NCODA will do for oncology dispensing what COA has done for community oncology by improving access to oral oncology drugs for America’s cancer patients and giving patients a voice in Washington. ”, said Dr. Brooks.

“Dr. Brooks, in addition to being an outstanding medical oncologist, is a dynamic individual who will bring a great deal of insight from a physician’s perspective to our NCODA initiatives” said Jim Schwartz, NCODA President and Executive Council Chair.

For more information about NCODA’s Executive Council and general updates visit or read the official release here.

Read More


March 29, 2019

Cazenovia, NY – The National Community Oncology Dispensing Association, Inc. (NCODA)is pleased to announce the addition of three new members to the Executive Council. Randy Erickson, RN, BSN, MBA, James Gilmore, PharmD, and Kirollos Hanna, PharmD, BCPS, BCOP joined the Council in March.

Randy Erickson currently serves as Chief Executive Officer at Utah Cancer Specialists in Salt Lake City, UT. He is a skilled healthcare professional with over 20 years of clinical experience. In his current role as CEO, Randy helps set the strategic course for the practice. Utah Cancer Specialists is the largest community-based oncology and hematology treatment practice in Utah, with physicians providing medical oncology, hematology, radiation oncology, and imaging services. ”Cancer care has become increasingly complex and with more oral therapies available, providing high quality care to our patients has never been more important. The overall patient experience is enhanced when physicians are able to dispense these medications within their own practices. NCODA is the perfect partner in helping practices improve pharmacy operations and enhance patient care,” said Randy. 

James Gilmore is the Executive Vice President at Georgia Cancer Specialists (GCS). GCS is a national leader in advanced cancer treatment and research. Their 50 physicians provide care in 26 Northside Hospital Cancer Institute locations across Metro Atlanta, and North and Central Georgia. ”I am very honored to serve on the Executive Council of NCODA. It has become one of the most important organizations in the oncology space. I look forward to helping NCODA to continue to grow and to ensure that our patients have access to live-saving therapies for years to come”, said Gilmore. 

Kirollos Hanna is board certified by the Board of Pharmacy Specialties in Oncology Pharmacy and Pharmacotherapy. He is currently an Assistant Professor of Pharmacy at the Mayo Clinic College of Medicine. He primarily practices Hematology/Oncology pharmacy at the University of Minnesota Medical Center and Mayo Clinic. ”It is an honor and privilege to serve patients through NCODA. The rapid growths in oral oncology therapeutics and practices have created large gaps in optimizing care and streamlining dispensing. As a firm believer in the NCODA mission of a patient-centered, medically-integrated dispensing model, I will continue to advocate for patients and best-practice initiatives”, said Hanna. Kirollos is an active member in NCODA committees and initiatives. He serves on the advisory board for the Treatment Support Kit (TSK) initiative, he is editor for the Positive Quality Intervention (PQI) initiative, he is serves on the oral chemotherapy education (OCE) steering committee, and he also serves as part of the editorial board for NCODA’s publication, Oncolytics Today.

“Over the last month we have added three highly skilled and well-respected oncology professionals to our Executive Council!” said Jim Schwartz, NCODA President and Executive Council Chair. “Randy, James, and Kirollos are well positioned to help us continue executing on our mission.”

For more information about NCODA’s Executive Council and general updates visit

See the Full Press Release HERE

Read More


March 15, 2019

NCODA Announces Dr. Mario Lacouture as Director of the Medical Advisory Board for Treatment Support Program

Cazenovia, NY – The National Community Oncology Dispensing Association, Inc. (NCODA) Executive Council is pleased to announce that Mario Lacouture, M.D. will be joining the Treatment Support Program as Director of the Medical Advisory Board.

Dr. Lacouture is a board-certified dermatologist at Memorial Sloan Kettering Cancer Center in New York City, where he serves as Director of the Oncodermatology Program. Dr. Lacouture’s clinical career has focused on the recognition and management of side effects resulting from cancer treatments, affecting the skin, hair, and nails of cancer patients and survivors.

“It is a great day for NCODA!” proclaimed Michael Reff, Founder and Executive Director of NCODA, after learning that Mario Lacouture would be joining the Treatment Support Program team. Dr. Lacouture will start his work with the program in March. In his role as Director of the Medical Advisory Board, Dr. Lacouture will be providing expertise and guidance to the program committee.

The mission of NCODA’s Treatment Support Program is to provide patients and caregivers with resources that make sense for adherence and adverse effect management during treatment with anticancer medications. The priority is to equip healthcare professionals and patients with educational information and products that will be needed during the course of treatment. NCODA’s Treatment Support Kits are a fundamental component of the program.

TSK committee co-chairs Chris Kepinski, PharmD [Southern Oncology Specialists, NC] and Jamie Fritz, PharmD [Compass Oncology, WA] also see Dr. Lacouture as a great asset to the program. “Having an expert on the team who has seen first-hand how adverse effects of cancer treatments impact patient adherence is extremely important,” Kepinski said.

“The work that NCODA is doing with the Treatment Support Program is something that I fully support,” said Lacouture. “What better way to help patients than by providing them with the information and products they need to maintain their quality of life and health throughout their treatment course.”

For more information about NCODA’s Treatment Support Program visit:

See Full Press Release Here.

Read More